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of neutropenia were identified.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
The judgement criteria used were not stated. Summary statistics from the study were used to extract the data.
Number of primary studies included
One randomised clinical trial was included in the review. Four other studies were also referred to although no details of their design were provided.
Methods of combining primary studies
This was not relevant as the results of only one study were used.
Investigation of differences between primary studies
The authors reported that three other studies had shown similar results while one had disagreed. The authors suggest that these inconsistencies arose from difficulties in estimating dose-response in non-randomised, retrospective studies.
Results of the review
The study demonstrated an 11% reduction in 3-year DFS with a 50% reduction in dosage. The 3-year DFS was 74% versus 63%.
Methods used to derive estimates of effectiveness
Authors' assumptions were used to derive estimates of likely future events of neutropenia, chemotherapy dose reduction, and dose delay.
Estimates of effectiveness and key assumptions
These estimates were reported in a companion paper and are not presented here.
Measure of benefits used in the economic analysis
Life years saved was the outcome measure used in the economic analysis. A conditional cost-effectiveness model was developed for the use of G-CSF based on a ranking of patient need, as determined by patient blood counts during the first cycle of chemotherapy. The model integrated estimates of outcome and costs and projected effectiveness and cost estimates beyond the timescale of direct observation.
Direct costs
Costs were discounted at a rate of 4%. Quantities and costs were not analysed separately. The health service costs of treatment measured were expenditures for G-CSF, chemotherapy, hospitalisation for fever and neutropenia, and outpatient administration of salvage chemotherapy and obtaining blood counts. The estimation of quantities and costs was derived using a modelling study. Seven doses of G-CSF per cycle were assumed, with a maximum of five cycles of G-CSF. Payment per hospital episode of febrile neutropenia was based on reimbursement rates for the Health Care Financing Administration's Diagnostic group 399 with a mean hospitalisation rate of 4.7 days. Costs of salvage therapy were based on paclitaxel as salvage therapy if cyclophosphamide, doxorubicin and fluorouracil (CAF) was the primary therapy, or CAF as the salvage therapy if cyclophosphamide, methotrexate and fluorouracil (CMF) was the primary therapy.
Indirect Costs
Indirect costs were not included.
Currency

US dollars ($).
Sensitivity analysis
One-way simple sensitivity analyses were performed for a range of model assumptions: discount rates, effectiveness data and cost data. A three-way sensitivity analysis of the influence of the dose-reduction assumptions on the results was also performed.
Estimated benefits used in the economic analysis
The incremental gains in life expectancy were not reported separately in the paper: only graphical illustrations of gains in life expectancy were provided. The authors reported that the gain in life expectancy was greater in the patients who received G-CSF than in those who had to wait until an event occurred. The group that received G-CSF would have less chance of dose reduction. Side effects of treatment were considered in the economic analysis.
Cost results
The total intervention cost was not reported separately in the paper: only graphical illustrations of total cost of treatment per patient and incremental cost per patient were provided. The authors noted that the cost savings of G-CSF (with respect to lowered hospitalisation and salvage costs) were less than the costs of giving G-CSF to all patients from cycles 2 through 6. On an incremental basis, as initial patient risk increases, incremental cost in the group starting on G-CSF in cycle 2 was declining, because the higher average hospitalisation expenditures of high-risk patients were reduced by G-CSF.
Synthesis of costs and benefits
At a threshold of risk of an event above which the decision-maker administers G-CSF equal to 0.48 (at which 50% of patients would receive G-CSF), the cost per life year saved was $34,297. If all patients were given G-CSF starting in cycle 2, the cost-effectiveness ratio increased to $254,925 per life year saved. If patients were not permitted to use G-CSF unless preceded by an event, the cost fell to $21,673 per life year saved.
These estimates were relatively insensitive to in-patient hospital cost estimates. However, the model was sensitive to assumptions about the shape of the relationship between dose reduction and disease-free survival at 3 years.
The reason for the choice of comparator was clear.
Validity of estimate of measure of benefit
As the authors indicated, the greatest imprecision in their analysis was associated with the sensitivity of their results to the shape of the dose-response curve, which, at the time of the study, was not known with precision. The thoroughness of the authors' attempts to identify relevant studies was not reported. Therefore, it is difficult to judge whether biases could have been introduced into the model.
Validity of estimate of costs
Resource quantities were not reported separately from prices and only partial details of the methods of quantity/cost estimation were provided. Cost results might not be generalisable outside the US setting. Furthermore, a discount rate of 4% was used in the cost analysis, which might not be relevant to other settings.
Other issues
To account for the uncertainties in the data the authors carried out extensive sensitivity analyses. Appropriate comparisons were made with other studies.
Implications of the study
